Cadila Launches Cadalimab (biosimilar, adalimumab) in India

 Cadila Launches Cadalimab (biosimilar, adalimumab) in India

Cadila Launches Cadalimab (biosimilar, adalimumab) in India

Shots:

  • Cadila has launched the adalimumab biosimilar under the brand name Cadalimab, referencing AbbVie’s Humira which is used to treat RA,PsA, AS and psoriasis
  • The launch strengthens Cadila’s biosimilar portfolio as Cadalimab is the fourth biosimilar launched in the last 2mos. following Bevaro, Ritucad and NuPTH for cancer and osteoporosis
  • Cadalimab is available in 40mg/0.8ml, easy pre-filled syringe and has shown a significant reduction in signs and symptoms of many diseases including RA, JIA, AS and PsA

Click here ­to­ read full press release/ article | Ref: Cadila  | Image: Cadila

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post